| Document |
Document Title |
|
WO/2023/039005A2 |
Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
|
|
WO/2023/034617A1 |
The present invention is directed to new methods for the treatment of an infection by a virus from the genus Flavivirus, particularly Dengue fever virus, Yellow Fever virus, Zika virus, and West Nile virus, in a host in need thereof, typ...
|
|
WO/2023/031481A1 |
The present invention relates to a method for preparing cyclic guanosine-3', 5'- monophosphate analogues. The invention also relates to the new cyclic guanosine-monophosphate analogues and intermediates obtained by the method.
|
|
WO/2023/033481A1 |
The present invention relates to an adenosine diphosphate-ribose (ADP-ribose) binding peptide having anticancer activity and, more particularly, to an ADP-ribose binding peptide of a specific amino acid sequence, a modified product there...
|
|
WO/2023/027178A1 |
The present invention relates to a method for producing a cytidine-5'-diphosphate compound, the method comprising: (1) a step in which a solution containing a cytidine-5'-diphosphate compound is brought into contact with a basic ion exch...
|
|
WO/2023/026449A1 |
The purpose of the present invention is to provide a method for producing a cytidine 5'-diphosphate compound, in which cytidine 5'-phosphate can be efficiently separated from a crude cytidine 5'-diphosphate compound to concentrate the cy...
|
|
WO/2023/027065A1 |
The present invention provides a novel method for producing a 2'-modified guanosine compound represented by the formula. In the formula, R1 and R2 may be the same or different, and each represents a hydrogen atom, an optionally substitut...
|
|
WO/2023/023550A1 |
The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linkage. In some embod...
|
|
WO/2023/021286A2 |
The present invention relates to novel nucleotide complexes which enhance the enzymatic production of DNA. The nucleotide complexes includes a divalent cation at a ratio of 0.2-1.5 divalent cations per nucleotide, whilst monovalent ions ...
|
|
WO/2023/023513A1 |
Provided herein are stable, modified oligonucleotides comprising a 5'-alkyl phosphate or derivatives thereof and methods for preparing the same.
|
|
WO/2023/019670A1 |
A purification method for fluorescein-labeled nucleoside triphosphate, specifically comprising: purifying a fluorescein-labeled nucleoside triphosphate crude product by means of liquid chromatography, and collecting a target fraction, wh...
|
|
WO/2023/016999A2 |
GalNAc monomers and GalNAc-oligonucleotide conjugates made using said GalNAc monomers, for example, GalNAc-bearing nucleic acids, e.g. sa-RNAs and siRNAs that may be useful in regulating expression of a target gene.
|
|
WO/2023/017152A1 |
The present invention relates to novel specific small molecule inhibitors that block KMT9 methyltransferase activity. In particular, the present invention is concerned with a compound of formula (I) wherein X1, X2, X3, X4, R1, R2, R3, R5...
|
|
WO/2023/007019A1 |
The present invention is inter alia concerned with (A) a compound of formula (I) as defined herein or a salt, stereoisomer, tautomer or deuterated version thereof, (B) a cap analog comprising a 5' terminal acyclonucleoside, wherein the a...
|
|
WO/2023/001982A1 |
The present invention relates to ligands specifically presented by MR1 molecules to MR1-specific T cells. These ligands are derivatives or analogues of nucleic acid forming bases, particularly ribonucleoside and deoxyribonucleoside adduc...
|
|
WO/2023/004130A1 |
Methods for synthesizing Bisphosphocins use chemical modification of dialcoholic compounds avoiding the use of tetrazole and tertiary butyl hydroperoxide.
|
|
WO/2023/004438A2 |
The present application provides compounds and methods for identifying a modulator of a protein of interest using TR-FRET donor attached to the protein of interest and a tracer containing TR-FRET acceptor.
|
|
WO/2023/000708A1 |
Disclosed are a polysubstituted purine compound as shown in formula (I), and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Also disclosed is that the compound has an obvious inhibitory eff...
|
|
WO/2023/288045A2 |
The present disclosure relates monomers and methods for synthesisizing oligonucleotides comprising 2,6-diaminopurine (DAP) and 2-aminoadenine conjugates.
|
|
WO/2023/288047A2 |
The present disclosure relates generally to monomers and methods for conjugating one or more ligands to oligonucleotides by Click chemistry at the anomeric site of pentose sugars, such as pentose sugars or hexose sugars.
|
|
WO/2023/282306A1 |
The present invention provides a pharmaceutical composition for treating or preventing a disease associated with the reduction or defect of the modification of 5-taurinomethyluridine (τm5U) in mitochondrial tRNA, the pharmaceutical comp...
|
|
WO/2023/282704A1 |
The present invention relates to an RNAi agent targeting a mitochondrial amidoxime reducing component 1 (MARC1) gene, and a use thereof, and, more specifically, to: an RNAi agent comprising an antisense strand having sequence complementa...
|
|
WO/2023/280156A1 |
Provided is a modified nucleoside or nucleotide. The modified nucleoside or nucleotide contains an N or S atom at a 3' position of a sugar ring, and can be used for NGS sequencing. Further provided are a kit comprising the modified nucle...
|
|
WO/2023/277630A1 |
A galactoside derivative according to the present invention has the effect of inhibiting galectin-3 by having a structure in which a spiro ring is fused to C1, and appropriate substituents at other carbon positions. Therefore, the galact...
|
|
WO/2022/271540A1 |
This document provides ((benzoimidazolyl)ethyl)cyclobutyl-containing compounds useful in treating cancer such as cholangiocarcinoma.
|
|
WO/2022/271878A1 |
The invention provides substituted 4-ethynyl-3-hydroxy-tetrahydrofuranyl-adenine phosphoramidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptas...
|
|
WO/2022/265964A1 |
Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 in...
|
|
WO/2022/262845A1 |
The present disclosure relates to ester derivatives of N 4-hydroxycytidine (NHC), to pharmaceutical compositions thereof, and to the use and method of the ester derivatives of N 4-hydroxycytidine to treat viral infections.
|
|
WO/2022/263489A1 |
Disclosed herein are base-modified nucleoside-5 '-oligophosphates (bm-N5OP) that include a positively charged moiety at least at one position of the base, compositions comprising the same, compositions made from the same, methods of maki...
|
|
WO/2022/266237A1 |
Deoxynucleotide prodrugs and methods of their use for treatment of diseases characterized by unbalanced nucleotide pools such as MPV17 and deoxyguanosine kinase deficiency are provided herein.
|
|
WO/2022/265054A1 |
To provide a hair growth stimulant that is a topical agent exhibiting effects such as promoting hair shaft growth in hairs such as scalp hair, beard hair, eyebrows and/or eyelashes, accelerating gene expression contributing to hair growt...
|
|
WO/2021/209425A9 |
The present disclosure is directed toward alkynyl nucleoside analogs, compositions comprising these compounds, and their use for treating hepatitis E infections.
|
|
WO/2022/266316A1 |
Embodiments of the present application relate to N-acetylgalactosamine-conjugated nucleosides. In particular, the N-acetylgalactosamine is installed on the nucleobase of the nucleosides through a wide variety of linkers. Methods of makin...
|
|
WO/2022/266322A1 |
The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndr...
|
|
WO/2022/258043A1 |
The present invention provides gemcitabine anticancer derivatives of formula (III) and the anticancer pharmaceutical use, which have the potential to be developed into AKR1C3-activated anticancer drugs.
|
|
WO/2022/260535A1 |
Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing an infection caused by Human Cytomegalovirus (HCMV), Epstein-Barr virus (EBV), or Human Immunodef...
|
|
WO/2022/260336A2 |
The present invention relates to a nucleoside derivative, which can be used for the prevention or treatment of cancer by inhibiting a kinase, and a pharmaceutical composition comprising same, wherein the nucleoside derivative has inhibit...
|
|
WO/2022/256490A2 |
The synthesis of phosphoramidate prodrugs useful in the treatment of viral infections is disclosed. Specifically, an improved synthesis of phosphoramidate nucleotides useful in the treatment of Hepatitis B virus is disclosed.
|
|
WO/2022/254376A1 |
The present disclosure provides neoDegraders and neoDegraders conjugated to binding moieties. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., ...
|
|
WO/2022/254457A1 |
The present invention relates to an improved process for the preparation of (4R)-1-[(2R, 4R, 5R)-3,3-difluoro-4-hydroxy-5- (hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one compound of formula-1 and its intermediate compounds. [F...
|
|
WO/2022/251032A1 |
A method for purifying nucleotides is provided, that includes preparing a solution comprising (a) 3'-blocked nucleotides, (b) 3'-OH nucleotides, (c) a polishing polymerase, and (d) a template. The polishing polymerase and the template ar...
|
|
WO/2022/248960A1 |
The present invention relates to solid forms of molnupiravir, including its co-crystals, solvates, hydrates and/or polymorphs, processes for their preparation, pharmaceutical compositions containing the same.
|
|
WO/2022/251594A1 |
The present invention relates to methods for treating a patient infected with hepatitis B virus (HBV) with a therapeutically effective amount of a a phosphoramidate prodrug of clevudine either alone or in combination with a second antivi...
|
|
WO/2022/245814A1 |
The invention provides methods and compositions for treating medical disorders, such as cancer, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase using a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic aci...
|
|
WO/2022/242540A1 |
Disclosed are a tri-coordinated phosphorus derivative, an intermediate, and a preparation method. The structural formula is as follows: R2 is a phenol group, a pentafluorophenol group, and a C1-4 alkoxy group, and the alkoxy group is opt...
|
|
WO/2022/245584A1 |
Provided herein are phosphoramidate and cyclophosphate prodrug compounds of unnatural configuration nucleotide, their preparation, and their uses, such as treating liver diseases or nonliver diseases via intervening in the molecular path...
|
|
WO/2022/238568A1 |
The invention relates to a prodrug formed from a compound comprising a pharmaceutically active antioxidant molecule which is covalently coupled, via a bond comprising at least one carboxylic ester group, to a nucleoside devoid of free hy...
|
|
WO/2022/240952A1 |
Oligonucleotide conjugates are provided herein that inhibit or reduce expression of target genes in the neurons of the central nervous system. Also provided are compositions including the same and uses thereof, particularly uses relating...
|
|
WO/2022/237747A1 |
Disclosed is a compound of formula (I), and a stereoisomer, a pharmaceutically acceptable salt, a solvate, a co-crystal or a deuterated product thereof, or a pharmaceutical composition containing same, and the use thereof as a CD73 antag...
|
|
WO/2022/238816A1 |
Bicyclic heterocyclic compounds and derivatives thereof that have antiviral properties are disclosed. Pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for the delivery of the compounds to a subject...
|
